Skip to content

The efficacy of penetrating canaloplasty vers canaloplasty in primary open angle glaucoma(POAG): A randomized controlled trial

The efficacy of penetrating canaloplasty vers canaloplasty in primary open angle glaucoma(POAG): A randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009034
Enrollment
Unknown
Registered
2016-08-16
Start date
2016-08-17
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Group 1:Penetrating Canaloplasty surgery (combine canaloplasty with trabeculectomy)
Group 2:Canaloplasty surgery

Sponsors

Ophthalmology and Optometry Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All patients were at least 18 years old at the time of enrollment, able to understand and provide informed consent, and were scheduled for glaucoma surgery or combined cataract and glaucoma surgery. A diagnosis of primary open-angle glaucoma (POAG), pigmentary glaucoma, or exfoliative glaucoma, and a historical IOP of 21 mmHg or higher. With many patients on maximally tolerated medical therapy, the protocol was designed to allow patients to withdraw from medications due to intolerance or poor compliance provided they had a historical IOP =21 mmHg. All patients had documented visual field loss, were in various stages of the disease, and met the individual criteria of each surgeon for the diagnosis of glaucoma and failure of prior medical or laser therapy.

Exclusion criteria

Exclusion criteria: (1) Severe heart, lung disease, advanced cancer,and with a history of mental illness; (2) A history of eye surgery and eye penetrate traumas; (3) Neovascular disease in fundus; (4) Refused to sign the informed consent and those who cannot adhere to the follow-up.

Design outcomes

Primary

MeasureTime frame
intraocular pressure;surgical success rate;

Secondary

MeasureTime frame
filtering bleb;anti-glaucoma medicine;

Countries

China

Contacts

Public ContactYuanbo Liang

Ophthalmology and Optometry Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China

yuanboliang@126.com+86 18257748686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026